#### **AMENDMENT**

Please amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

### **Amendment to the Claims**:

This listing of claims will replace all prior versions, and listings, of claims in the application:

#### **Listing of Claims:**

Claim 1(currently amended): A compound having the formula (I):

or a pharmaceutically acceptable salts thereof, wherein

NonAr is a nonaromatic [5-7] <u>6</u> membered ring containing 1 [or 2] nitrogen ring atoms or an aza bicyclo octane ring;

HetAr is a 5 or 6 membered heteroaromatic ring containing 1-3 nitrogen ring atoms, or isoxazolyl, thiazolyl, thiadiazolyl, quinolinyl, quinazolinyl, purinyl, pteridinyl, benzimidazolyl, pyrrolopyrimidinyl, or imidazopyridinyl;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C<sub>1</sub>-4alkyl, C<sub>1</sub>-4alkoxy, C<sub>2</sub>-4alkynyl, trifluoromethyl, hydroxy, hydroxyC<sub>1</sub>-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C<sub>0</sub>-4alkyl)(C<sub>0</sub>-4alkyl), nitro, (C<sub>1</sub>-2alkyl)(C<sub>1</sub>-2alkyl)NCH<sub>2</sub>-, (C<sub>1</sub>-2alkyl)HNCH<sub>2</sub>-, Si(CH<sub>3</sub>)<sub>3</sub>-C-, or NH<sub>2</sub>C(O)-;

A is  $-C_{0-4}$ alkyl-;

B is aryl(CH<sub>2</sub>)<sub>0-3</sub>-O-C(O)-, heteroaryl(CH<sub>2</sub>)<sub>1-3</sub>-O-C(O)-, indanyl(CH<sub>2</sub>)<sub>0-3</sub>-O-C(O)-, aryl(CH<sub>2</sub>)<sub>1-3</sub>-C(O)-, aryl-cyclopropyl-C(O)-, heteroaryl-cyclopropyl-C(O)-, heteroaryl(CH<sub>2</sub>)<sub>1-3</sub>-C(O)-, [[aryl(CH<sub>2</sub>)<sub>1-3</sub>-]], [[heteroaryl(CH<sub>2</sub>)<sub>1-3</sub>-,]] aryl(CH<sub>2</sub>)<sub>1-3</sub>-NH-C(O)-, aryl(CH<sub>2</sub>)<sub>1-3</sub>-NH-C(NCN)-, aryl(CH<sub>2</sub>)<sub>1-3</sub>-SO<sub>2</sub>-, heteroaryl(CH<sub>2</sub>)<sub>1-3</sub>-SO<sub>2</sub>-, wherein any of the aryl or heteroaryl is optionally substituted by 1-5 substitutents, each substituent independently is C<sub>1</sub>-4alkyl, C<sub>3</sub>-6cycloalkyl, C<sub>1</sub>-4alkoxy, trifluoromethyl, bromo, fluoro, or chloro; and X is H. OH. F. C<sub>1</sub>-4alkyl, C<sub>1</sub>-4alkoxy, NH<sub>2</sub>, or X taken with an adjacent bond is

X is H, OH, F, C<sub>1</sub>-4alkyl, C<sub>1</sub>-4alkoxy, NH<sub>2</sub>, or X taken with an adjacent bond is =0.

Claim 2(previously presented): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and B is aryl(CH<sub>2</sub>)<sub>0-3</sub>–O–C(O)–, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C<sub>1-4</sub>alkyl, C<sub>3-6</sub>cycloalkyl, C<sub>1-4</sub>alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 3(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 1 nitrogen ring atom;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is  $C_{1-4}$ alkyl,  $C_{1-4}$ alkoxy,  $C_{2-4}$ alkynyl, trifluoromethyl, hydroxy, hydroxy $C_{1-4}$ alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—, $-N(C_{0-4}$ alkyl)( $C_{0-4}$ alkyl), nitro, ( $C_{1-2}$ alkyl)( $C_{1-2}$ alkyl)NCH2—, ( $C_{1-2}$ alkyl)HNCH2—, Si(CH3)3—C—, or NH2C(O)—.

Claim 4(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is an isoxazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, C<sub>2-4</sub>alkynyl, trifluoromethyl, hydroxy, hydroxyC<sub>1-4</sub>alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-,

Serial No.: 10/079,452 Case No.: 20832Y

Page No.: 5

phenylethynyl-, heteroarylethynyl-,- $N(C_0$ -4alkyl)( $C_0$ -4alkyl), nitro, ( $C_1$ -2alkyl)( $C_1$ -2alkyl)NCH2-, ( $C_1$ -2alkyl)HNCH2-, Si(CH3)3-C-, or NH2C(O)-.

Claim 5(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a thiadiazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, C<sub>2-4</sub>alkynyl, trifluoromethyl, hydroxy, hydroxyC<sub>1-4</sub>alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C<sub>0-4</sub>alkyl)(C<sub>0-4</sub>alkyl), nitro, (C<sub>1-2</sub>alkyl)(C<sub>1-2</sub>alkyl)NCH<sub>2</sub>-, (C<sub>1-2</sub>alkyl)HNCH<sub>2</sub>-, Si(CH<sub>3</sub>)<sub>3</sub>-C-, or NH<sub>2</sub>C(O)-.

Claim 6(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 5 membered heteroaromatic ring containing 2 nitrogen ring atoms; HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C<sub>1</sub>-4alkyl, C<sub>1</sub>-4alkoxy, C<sub>2</sub>-4alkynyl, trifluoromethyl, hydroxy, hydroxyC<sub>1</sub>-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C<sub>0</sub>-4alkyl)(C<sub>0</sub>-4alkyl), nitro, (C<sub>1</sub>-2alkyl)(C<sub>1</sub>-2alkyl)NCH<sub>2</sub>-, (C<sub>1</sub>-2alkyl)HNCH<sub>2</sub>-, Si(CH<sub>3</sub>)<sub>3</sub>-C-, or NH<sub>2</sub>C(O)-.

Claim 7(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is quinolinyl optionally substituted with 1 or 2 substituents, each substituent independently is C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, C<sub>2-4</sub>alkynyl, trifluoromethyl, hydroxy, hydroxyC<sub>1-4</sub>alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,-N(C<sub>0-4</sub>alkyl)(C<sub>0-4</sub>alkyl), nitro, (C<sub>1-2</sub>alkyl)(C<sub>1-2</sub>alkyl)NCH<sub>2</sub>-, (C<sub>1-2</sub>alkyl)HNCH<sub>2</sub>-, Si(CH<sub>3</sub>)<sub>3</sub>-C-, or NH<sub>2</sub>C(O)-.

Claim 8(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, C<sub>2-4</sub>alkynyl, trifluoromethyl, hydroxy, hydroxyC<sub>1-</sub>

4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,— $N(C_0$ -4alkyl)( $C_0$ -4alkyl), nitro, ( $C_1$ -2alkyl)( $C_1$ -2alkyl)NCH2—, ( $C_1$ -2alkyl)HNCH2—, Si(CH3)3—C—, or NH2C(O)—.

Claim 9(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atoms; HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C<sub>1</sub>-4alkyl, C<sub>1</sub>-4alkoxy, C<sub>2</sub>-4alkynyl, trifluoromethyl, hydroxy, hydroxyC<sub>1</sub>-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C<sub>0</sub>-4alkyl)(C<sub>0</sub>-4alkyl), nitro, (C<sub>1</sub>-2alkyl)(C<sub>1</sub>-2alkyl)NCH<sub>2</sub>-, (C<sub>1</sub>-2alkyl)HNCH<sub>2</sub>-, Si(CH<sub>3</sub>)<sub>3</sub>-C-, or NH<sub>2</sub>C(O)-.

Claim 10(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is thiazolyl optionally substituted with 1 or 2 substituents, each substituent independently is  $C_{1-4}$ alkyl,  $C_{1-4}$ alkoxy,  $C_{2-4}$ alkynyl, trifluoromethyl, hydroxy, hydroxy $C_{1-4}$ alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,— $N(C_{0-4}$ alkyl)( $C_{0-4}$ alkyl), nitro, ( $C_{1-2}$ alkyl)( $C_{1-2}$ alkyl)NCH2—, ( $C_{1-2}$ alkyl)HNCH2—, Si(CH3)3—C—, or NH2C(O)—.

Claim 11 (previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pteridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C<sub>1</sub>-4alkyl, C<sub>1</sub>-4alkoxy, C<sub>2</sub>-4alkynyl, trifluoromethyl, hydroxy, hydroxyC<sub>1</sub>-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C<sub>0</sub>-4alkyl)(C<sub>0</sub>-4alkyl), nitro, (C<sub>1</sub>-2alkyl)(C<sub>1</sub>-2alkyl)NCH<sub>2</sub>-, (C<sub>1</sub>-2alkyl)HNCH<sub>2</sub>-, Si(CH<sub>3</sub>)<sub>3</sub>-C-, or NH<sub>2</sub>C(O)-.

Claim 12(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pyrrolopyrimidinyl optionally substituted with 1 or 2 substituents, each substituent independently is C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, C<sub>2-4</sub>alkynyl, trifluoromethyl, hydroxy, hydroxyC<sub>1-4</sub>alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,-N(C<sub>0-4</sub>alkyl)(C<sub>0-4</sub>alkyl), nitro, (C<sub>1-2</sub>alkyl)(C<sub>1-2</sub>alkyl)NCH<sub>2</sub>-, (C<sub>1-2</sub>alkyl)HNCH<sub>2</sub>-, Si(CH<sub>3</sub>)<sub>3</sub>-C-, or NH<sub>2</sub>C(O)-.

Claim 13(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a imidazopyridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, C<sub>2-4</sub>alkynyl, trifluoromethyl, hydroxy, hydroxyC<sub>1-4</sub>alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C<sub>0-4</sub>alkyl)(C<sub>0-4</sub>alkyl), nitro, (C<sub>1-2</sub>alkyl)(C<sub>1-2</sub>alkyl)NCH<sub>2</sub>-, (C<sub>1-2</sub>alkyl)HNCH<sub>2</sub>-, Si(CH<sub>3</sub>)<sub>3</sub>-C-, or NH<sub>2</sub>C(O)-.

Claim 14(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is benzimidazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, C<sub>2-4</sub>alkynyl, trifluoromethyl, hydroxy, hydroxyC<sub>1-4</sub>alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,-N(C<sub>0-4</sub>alkyl)(C<sub>0-4</sub>alkyl), nitro, (C<sub>1-2</sub>alkyl)(C<sub>1-2</sub>alkyl)NCH<sub>2</sub>–, (C<sub>1-2</sub>alkyl)HNCH<sub>2</sub>–, Si(CH<sub>3</sub>)<sub>3</sub>–C–, or NH<sub>2</sub>C(O)–.

Claim 15(previously presented): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and B is aryl(CH<sub>2</sub>)<sub>1-3</sub>–SO<sub>2</sub>–, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C<sub>1-4</sub>alkyl, C<sub>3-6</sub>cycloalkyl, C<sub>1-4</sub>alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 16(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atoms;

Serial No.: 10/079,452 Case No.: 20832Y

Page No.: 8

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is  $C_1$ -4alkyl,  $C_1$ -4alkoxy,  $C_2$ -4alkynyl, trifluoromethyl, hydroxy, hydroxy $C_1$ -4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,-N( $C_0$ -4alkyl)( $C_0$ -4alkyl), nitro, ( $C_1$ -2alkyl)( $C_1$ -2alkyl)NCH2—, ( $C_1$ -2alkyl)HNCH2—, Si( $C_1$ -3alkyl)-C—, or NH2C( $C_1$ -2alkyl)-C—.

Claim 17(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

HetAr is quinazolinyl optionally substituted with 1 or 2 substituents, each substituent independently is C<sub>1</sub>-4alkyl, C<sub>1</sub>-4alkoxy, C<sub>2</sub>-4alkynyl, trifluoromethyl, hydroxy, hydroxyC<sub>1</sub>-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,-N(C<sub>0</sub>-4alkyl)(C<sub>0</sub>-4alkyl), nitro, (C<sub>1</sub>-2alkyl)(C<sub>1</sub>-2alkyl)NCH<sub>2</sub>-, (C<sub>1</sub>-2alkyl)HNCH<sub>2</sub>-, Si(CH<sub>3</sub>)<sub>3</sub>-C-, or NH<sub>2</sub>C(O)-.

Claim 18(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C<sub>1</sub>-4alkyl, C<sub>1</sub>-4alkoxy, C<sub>2</sub>-4alkynyl, trifluoromethyl, hydroxy, hydroxyC<sub>1</sub>-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,-N(C<sub>0</sub>-4alkyl)(C<sub>0</sub>-4alkyl), nitro, (C<sub>1</sub>-2alkyl)(C<sub>1</sub>-2alkyl)NCH<sub>2</sub>-, (C<sub>1</sub>-2alkyl)HNCH<sub>2</sub>-, Si(CH<sub>3</sub>)<sub>3</sub>-C-, or NH<sub>2</sub>C(O)–.

Claim 19(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

HetAr is imidazopyridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C<sub>1</sub>-4alkyl, C<sub>1</sub>-4alkoxy, C<sub>2</sub>-4alkynyl, trifluoromethyl, hydroxy, hydroxyC<sub>1</sub>-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,-N(C<sub>0</sub>-4alkyl)(C<sub>0</sub>-4alkyl), nitro, (C<sub>1</sub>-2alkyl)(C<sub>1</sub>-2alkyl)NCH<sub>2</sub>-, (C<sub>1</sub>-2alkyl)HNCH<sub>2</sub>-, Si(CH<sub>3</sub>)<sub>3</sub>-C-, or NH<sub>2</sub>C(O)-.

Claim 20(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 1 nitrogen ring atom; and HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C<sub>1</sub>-4alkyl, C<sub>1</sub>-4alkoxy, C<sub>2</sub>-4alkynyl, trifluoromethyl, hydroxy, hydroxyC<sub>1</sub>-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C<sub>0</sub>-4alkyl)(C<sub>0</sub>-4alkyl), nitro, (C<sub>1</sub>-2alkyl)(C<sub>1</sub>-2alkyl)NCH<sub>2</sub>-, (C<sub>1</sub>-2alkyl)HNCH<sub>2</sub>-, Si(CH<sub>3</sub>)<sub>3</sub>-C-, or NH<sub>2</sub>C(O)-.

Claim 21(withdrawn): The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

NonAr is a nonaromatic 5 membered ring containing 1 nitrogen ring atom; and B is aryl(CH<sub>2</sub>)<sub>0-3</sub>-O-C(O)-, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C<sub>1-4</sub>alkyl, C<sub>3-6</sub>cycloalkyl, C<sub>1-4</sub>alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 22(withdrawn): The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atoms; HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C<sub>1</sub>-4alkyl, C<sub>1</sub>-4alkoxy, C<sub>2</sub>-4alkynyl, trifluoromethyl, hydroxy, hydroxyC<sub>1</sub>-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C<sub>0</sub>-4alkyl)(C<sub>0</sub>-4alkyl), nitro, (C<sub>1</sub>-2alkyl)(C<sub>1</sub>-2alkyl)NCH<sub>2</sub>-, (C<sub>1</sub>-2alkyl)HNCH<sub>2</sub>-, Si(CH<sub>3</sub>)<sub>3</sub>-C-, or NH<sub>2</sub>C(O)-.

Claim 23(withdrawn): The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

HetAr is pteridinyl optionally substituted with 1 or 2 substituents, each substituent independently is  $C_1$ -4alkyl,  $C_1$ -4alkoxy,  $C_2$ -4alkynyl, trifluoromethyl, hydroxy, hydroxy $C_1$ -4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,- $N(C_0$ -4alkyl)( $C_0$ -4alkyl), nitro, ( $C_1$ -2alkyl)( $C_1$ -2alkyl)NCH2—, ( $C_1$ -2alkyl)HNCH2—, Si(CH3)3—C—, or NH2C(O)—.

Claim 24(withdrawn): The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C<sub>1</sub>-4alkyl, C<sub>1</sub>-4alkoxy, C<sub>2</sub>-4alkynyl, trifluoromethyl, hydroxy, hydroxyC<sub>1</sub>-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C<sub>0</sub>-4alkyl)(C<sub>0</sub>-4alkyl), nitro, (C<sub>1</sub>-2alkyl)(C<sub>1</sub>-2alkyl)NCH<sub>2</sub>-, (C<sub>1</sub>-2alkyl)HNCH<sub>2</sub>-, Si(CH<sub>3</sub>)<sub>3</sub>-C-, or NH<sub>2</sub>C(O)-.

Claim 25(withdrawn): The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

HetAr is benzimidazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, C<sub>2-4</sub>alkynyl, trifluoromethyl, hydroxy, hydroxyC<sub>1-4</sub>alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,-N(C<sub>0-4</sub>alkyl)(C<sub>0-4</sub>alkyl), nitro, (C<sub>1-2</sub>alkyl)(C<sub>1-2</sub>alkyl)NCH<sub>2</sub>-, (C<sub>1-2</sub>alkyl)HNCH<sub>2</sub>-, Si(CH<sub>3</sub>)<sub>3</sub>-C-, or NH<sub>2</sub>C(O)-.

Claim 26(withdrawn): The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

NonAr is an aza bicyclo octane ring; and

B is  $aryl(CH_2)_{0-3}$ –O–C(O)–, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C<sub>1-4</sub>alkyl, C<sub>3-6</sub>cycloalkyl, C<sub>1-4</sub>alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 27(withdrawn): The compound according to Claim 26, or pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 1 nitrogen ring atom; and HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C<sub>1</sub>-4alkyl, C<sub>1</sub>-4alkoxy, C<sub>2</sub>-4alkynyl, trifluoromethyl, hydroxy, hydroxyC<sub>1</sub>-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C<sub>0</sub>-4alkyl)(C<sub>0</sub>-4alkyl), nitro, (C<sub>1</sub>-2alkyl)(C<sub>1</sub>-2alkyl)NCH<sub>2</sub>-, (C<sub>1</sub>-2alkyl)HNCH<sub>2</sub>-, Si(CH<sub>3</sub>)<sub>3</sub>-C-, or NH<sub>2</sub>C(O)-.

Claim 28(withdrawn): The compound according to Claim 26, or pharmaceutically acceptable salts thereof, wherein

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C<sub>1</sub>-4alkyl, C<sub>1</sub>-4alkoxy, C<sub>2</sub>-4alkynyl, trifluoromethyl, hydroxy, hydroxyC<sub>1</sub>-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C<sub>0</sub>-4alkyl)(C<sub>0</sub>-4alkyl), nitro, (C<sub>1</sub>-2alkyl)(C<sub>1</sub>-2alkyl)NCH<sub>2</sub>-, (C<sub>1</sub>-2alkyl)HNCH<sub>2</sub>-, Si(CH<sub>3</sub>)<sub>3</sub>-C-, or NH<sub>2</sub>C(O)-.

Claim 29(withdrawn): The compound according to Claim 26, or pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atom; and HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C<sub>1</sub>-4alkyl, C<sub>1</sub>-4alkoxy, C<sub>2</sub>-4alkynyl, trifluoromethyl, hydroxy, hydroxyC<sub>1</sub>-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C<sub>0</sub>-4alkyl)(C<sub>0</sub>-4alkyl), nitro, (C<sub>1</sub>-2alkyl)(C<sub>1</sub>-2alkyl)NCH<sub>2</sub>-, (C<sub>1</sub>-2alkyl)HNCH<sub>2</sub>-, Si(CH<sub>3</sub>)<sub>3</sub>-C-, or NH<sub>2</sub>C(O)-.

Claim 30(withdrawn): The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

NonAr is an aza bicyclo octane ring; and

B is  $aryl(CH_2)_{1-3}$ –SO<sub>2</sub>–, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C<sub>1-4</sub>alkyl, C<sub>3-6</sub>cycloalkyl, C<sub>1-4</sub>alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 31(previously presented): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and B is heteroaryl(CH<sub>2</sub>)<sub>1-3</sub>-C(O)-, wherein the heteroaryl is optionally substituted by 1-5 substitutents, each substituent independently is C<sub>1</sub>-4alkyl, C<sub>3</sub>-6cycloalkyl, C<sub>1</sub>-4alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 32(previously presented): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and B is aryl(CH<sub>2</sub>)<sub>1-3</sub>-C(O)-, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C<sub>1-4</sub>alkyl, C<sub>3-6</sub>cycloalkyl, C<sub>1-4</sub>alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 33(previously presented): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and B is aryl-cyclopropyl-C(O)-, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C<sub>1-4</sub>alkyl, C<sub>3-6</sub>cycloalkyl, C<sub>1-4</sub>alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 34(previously presented): The compound according to Claim 33, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pyridyl optionally substituted with 1 or 2 substituents, each substituent independently is  $C_1$ -4alkyl,  $C_1$ -4alkoxy,  $C_2$ -4alkynyl, trifluoromethyl, hydroxy, hydroxy $C_1$ -4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,— $N(C_0$ -4alkyl)( $C_0$ -4alkyl), nitro, ( $C_1$ -2alkyl)( $C_1$ -2alkyl)NCH2—, ( $C_1$ -2alkyl)HNCH2—, Si(CH3)3—C—, or NH2C(O)—.

Claim 35(previously presented): The compound according to Claim 33, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pyrazinyl optionally substituted with 1 or 2 substituents, each substituent independently is C<sub>1</sub>-4alkyl, C<sub>1</sub>-4alkoxy, C<sub>2</sub>-4alkynyl, trifluoromethyl, hydroxy, hydroxyC<sub>1</sub>-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,-N(C<sub>0</sub>-4alkyl)(C<sub>0</sub>-4alkyl), nitro, (C<sub>1</sub>-2alkyl)(C<sub>1</sub>-2alkyl)NCH<sub>2</sub>-, (C<sub>1</sub>-2alkyl)HNCH<sub>2</sub>-, Si(CH<sub>3</sub>)<sub>3</sub>-C-, or NH<sub>2</sub>C(O)–.

Claim 36(previously presented): The compound according to Claim 33, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pyridazinyl optionally substituted with 1 or 2 substituents, each substituent independently is C<sub>1</sub>-4alkyl, C<sub>1</sub>-4alkoxy, C<sub>2</sub>-4alkynyl, trifluoromethyl, hydroxy, hydroxyC<sub>1</sub>-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,–N(C<sub>0</sub>-4alkyl)(C<sub>0</sub>-4alkyl), nitro, (C<sub>1</sub>-2alkyl)(C<sub>1</sub>-2alkyl)NCH<sub>2</sub>-, (C<sub>1</sub>-2alkyl)HNCH<sub>2</sub>-, Si(CH<sub>3</sub>)<sub>3</sub>-C-, or NH<sub>2</sub>C(O)-.

Claim 37(previously presented): The compound according to Claim 33, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pyrimidinyl optionally substituted with 1 or 2 substituents, each substituent independently is C<sub>1</sub>-4alkyl, C<sub>1</sub>-4alkoxy, C<sub>2</sub>-4alkynyl, trifluoromethyl, hydroxy, hydroxyC<sub>1</sub>-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,-N(C<sub>0</sub>-4alkyl)(C<sub>0</sub>-4alkyl), nitro, (C<sub>1</sub>-2alkyl)(C<sub>1</sub>-2alkyl)NCH<sub>2</sub>-, (C<sub>1</sub>-2alkyl)HNCH<sub>2</sub>-, Si(CH<sub>3</sub>)<sub>3</sub>-C-, or NH<sub>2</sub>C(O)-.

Claim 38(previously presented): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and B is heteroaryl(CH<sub>2</sub>)<sub>1-3</sub>–O–C(O)–, wherein the heteroaryl is optionally substituted by 1-5 substitutents, each substituent independently is C<sub>1-4</sub>alkyl, C<sub>3-6</sub>cycloalkyl, C<sub>1-4</sub>alkoxy, trifluoromethyl, bromo, fluoro, or chloro;.

Claim 39(previously presented): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and B is aryl(CH<sub>2</sub>)<sub>1-3</sub>-NH-C(NCN)-, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C<sub>1</sub>-4alkyl, C<sub>3</sub>-6cycloalkyl, C<sub>1</sub>-4alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 40(original): The compound according to Claim 1, wherein said compound is

10/079,452 20832Y 14

	NH NH O	
		ZZ
NH NH O		N H N O

10/079,452 20832Y 15 Page No.:

		NH <sub>2</sub> NH <sub>2</sub> NH <sub>2</sub> NH <sub>2</sub> NH <sub>2</sub> NH <sub>3</sub> NH <sub>4</sub> NH <sub>4</sub> NH <sub>4</sub> NH <sub>5</sub> NH <sub>5</sub> NH <sub>6</sub>
		N N N OH
F N N N N N N N N N N N N N N N N N N N	CI NO H	

10/079,452 20832Y 16

	O N H	
-0 -N -HN-(N		
F N N N N N N N N N N N N N N N N N N N	CI N H N	N OH OH
N OH	CH <sub>3</sub>	OH HN N
O N NC	O N HN N	HN N F <sub>3</sub> C

10/079,452 20832Y 17

O N HN N CI N	N H N H	
HO_NHON-O	N-N-NH-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-	HN-NH-NH-NH-NH-NH-NH-NH-NH-NH-NH-NH-NH-N
	OH H	Br NH O
F NH NH		
CI NH NH O		

10/079,452 20832Y 18

	F N N N N N N N N N N N N N N N N N N N	ZH2 ZH ZH Z
		F N N N N N N N N N N N N N N N N N N N
		CI NH NH NH
		D Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
F (N)	CI N N N N N N N N N N N N N N N N N N N	F HZ Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
	NH NH O	N HN O

10/079,452 20832Y

Page No.:

19

HN N O	HN N N O	HN N
N—HN—N—O		

or a pharmaceutically acceptable salt thereof.

Claim 41(original): The compound according to Claim 1, wherein said compound is

	N HN O O O O O O O O O O O O O O O O O O	
N NH OIL S	H <sub>2</sub> N—NH—N—SI	N N N N N N N N N N N N N N N N N N N
N N- N-NH O II N-S II	N—NH—OH—SH	N—NH 0 = N = N = N = N = N = N = N = N = N =

10/079,452 20832Y

Page No.:

20832

	NH O S S S S S S S S S S S S S S S S S S	N N N N N N N N N N N N N N N N N N N
N-NH O=S	F—NH O III	NH 0 = s
N-NH 0-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1	H <sub>2</sub> N	HN NH O===0

or a pharmaceutically acceptable salt thereof.

## Claim 42(currently amended): A compound is represented by

### The compound according to Claim 1, wherein said

or a pharmaceutically acceptable salt thereof.

20832Ý

Page No.:

21

10/079,452

# Claim 43(currently amended): compound is-represented by

### The compound according to Claim 1, wherein said A

or a pharmaceutically acceptable salt thereof.

Claim 44(previously presented): The compound according to Claim 1, wherein said compound is

Serial No.: Case No.: Page No.:

10/079,452 20832Y 22

CI N	
	HN N N
HN N NH <sub>2</sub>	

10/079,452 20832Y

Page No.:

23

		O N H N N N N N N N N N N N N N N N N N
P N H N N	O N N N N N N N N N N N N N N N N N N N	

or a pharmaceutically acceptable salt thereof.

Claim 45(previously presented): The compound according to Claim 1, wherein said compound is

Serial No.: Case No.: Page No.:

10/079,452 20832Y 24

		F N N N N N N N N N N N N N N N N N N N
F N N N N N N N N N N N N N N N N N N N	F N N N F F	N-N-F
HN-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-	N H N N N N N N N N N N N N N N N N N N	

10/079,452 20832Y 25

Page No.:

F N N N N N N N N N N N N N N N N N N N	HZ Z	N= N-Br
HIN-N-SI-	N= N= N= N= N=	N= HN-N= N-
N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-		
H N N N N N N N N N N N N N N N N N N N	LN LN LO CI	
H N N P F	H N N N N N N N N N N N N N N N N N N N	

Serial No.: 10/079,452 Case No.: 20832Y

Page No.: 26

	N N N N F	H N N N N N N N N N N N N N N N N N N N
	T N N N N N N N N N N N N N N N N N N N	
F N N F F F	F N N N N N N N N N N N N N N N N N N N	F N N N N N N N N N N N N N N N N N N N
ON H F	D, D D D D D D D D D D D D D D D D D D	O ZH

or a pharmaceutically acceptable salt thereof.

Claim 46(previously presented): The compound according to Claim 1, wherein said compound is

or a pharmaceutically acceptable salt thereof.

Claim 47(currently amended): A compound is represented by

The compound according to Claim 1, wherein said

or a pharmaceutically acceptable salt thereof.

Claim 48(original): A pharmaceutical composition comprising an inert carrier and an effective amount of a compound according to claim 1.

Claim 49(previously presented): A pharmaceutical composition comprising an inert carrier and an amount of a compound according to claim 1 effective to treat pain.

Claim 50(previously presented): A pharmaceutical composition comprising an inert carrier and an amount of a compound according to claim 1 effective to treat migraine, depression, anxiety, schizophrenia, Parkinson's disease, or stroke.

Claim 51(original): A method of treating pain comprising a step of administering to one in need of such treatment an effective amount of a compound according to claim 1.

Claim 52(original): A method of treating migraine, depression, anxiety, schizophrenia, Parkinson's disease, or stroke comprising a step of administering to one in need of such treatment an effective amount of a compound according to claim 1.